The Food and Drug Administration on Tuesday approved Novo Nordisk’s Ozempic for patients with chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. 

tag:reuters.com,2023:binary_RC28G3A9AAW8-BASEIMAGE

Benzinga

New York

United States

Ozempic Receives FDA Approval To Treat Kidney Disease - Novo Nordisk (NYSE:NVO)

Natco Pharma receives U.S. FDA approval for Everolimus tablets; to launch generic version of Afinitor Disperz in the U.S. market

Media Bias/Fact Check

The Hindu

The Hindu Group

India

U.S. FDA nod for Natco Pharma’s generic of Novartis drug

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday.

Ad Fontes Media

All Sides

Warner Bros. Discovery

Atlanta

Fulton County

Georgia

FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients

Approval is the most recent example of how Ozempic and other similar drugs, called GLP-1s, are being used to treat diabetes-related conditions, such as heart disease

Aprovação é o exemplo mais recente de como o Ozempic e outros remédios semelhantes, chamados GLP-1s, estão sendo usados ​​para tratar condições relacionadas ao diabetes, como doenças cardíacas

Ozempic obtém aprovação nos EUA para tratar doença renal

Globo

Roberto Irineu Marinho

Brazil

Ozempic obtains approval in the US to treat kidney disease

Ozempic's expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

CNBC

Roberts family

FDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease, expanding its use

The Food and Drug Administration on Tuesday approved Ozempic, the weight loss drug made by Novo Nordisk A/S (NYSE:NVO), for the treatment of chronic kidney disease in patients who also have type 2 diabetes.  The Details: According to the Centers for Disease Control and Prevention, more than 35.5 million Americans have chronic kidney disease, often as a complication of type 2 diabetes. The new FDA approval allows for further expansion of Ozempic'…

The patent for Ozempic ends in 2026 in Brazil, opening space for the production of generic and cheaper versions of the drug, but Novo Nordisk is trying to extend the deadline. The pharmacist argues that it is actually seeking compensation for the 13-year delay in the process of examining and granting a patent for semaglutide - the active ingredient in Ozempic - in the country, used to treat diabetes and obesity.
Read more (01/28/2025)

A patente do Ozempic se encerra em 2026 no Brasil, abrindo espa�o para a produ��o de vers�es gen�ricas e mais baratas do medicamento, mas a Novo Nordisk tenta ampliar o prazo. A farmac�utica argumenta que na verdade pleiteia uma compensa��o pelo atraso de 13 anos no processo de exame e concess�o da patente da semaglutida -princ�pio ativo do Ozempic- no pa�s, usada para tratamento de diabetes e obesidade.
Leia mais (01/28/2025

Novo Nordisk busca compensação na patente do Ozempic - 28/01/2025 - Equilíbrio e Saúde

Grupo Folha

Novo Nordisk seeks compensation in the Ozempic patent - 28/01/2025 - Balance and Health

Drugmaker Novo Nordisk said on Jan. 28 that the U.S. Food and Drug Administration (FDA) had approved Ozempic for lowering the risk of kidney failure and disease progression in adults with Type 2 diabetes.
The semaglutide medication is also approved for reducing the risk of death from cardiovascular disease in patients with Type 2 diabetes and chronic kidney disease, according to Novo Nordisk’s statement.
The Danish drugmaker stated that the FDA’…

The Epoch Times

Epoch Media Group

FDA Approves Ozempic for Lowering Kidney Disease Risks in Adults With Diabetes

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce certain risks associated with chronic kidney disease.

KCRA 3

Hearst Communications

Sacramento

Sacramento County

California

Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease, drugmaker Novo Nordisk said Tuesday.

abc 7 LA

The Walt Disney Company

Los Angeles

Los Angeles County

WCVB

Boston

Suffolk County

Massachusetts

Ozempic

Diabetes

Research

Novo Nordisk

Health

Medical

Medical Xpress

WLWT

Svenska Dagbladet

WMUR

News Medical

WLKY

WESH

Koco News5

WDSU

WYFF

KETV

WTAE

KCCI

KMBC

WISN

Medscape

WBAL-TV

WPTZ

WMTW

Politiken

WVTM

WAPT

KOAT

WSVN

WPBF

WGAL

WXII

East Idaho News

KSBW

KEYT

KMIZ

WJCL

KION

BizToc

KHBS

El Economista

Quartz

Investing.com

MOR-TV

Mediafax

HealthDay

Straight Arrow News

WJAR

NewsX

STAT

MedPage Today

Kenya Times Trending, Breaking News and Videos

MedCity News

Stockxpo - A professional network of traders, investors and analysts

pipelinereview

Verywell Health

Express Pharma

european-biotechnology.com

La Opinion

Bitcoin Ethereum News

Aleph News

Daily Expert News

Sky News: The Latest News from the World

thevoice.us

beckershospitalreview.com

ramaonhealthcare.com

Endpoints News

abbonews.com

Pharmacy Times

Pharmaphorum

ajmc.com

hcplive.com

Busines and Oil News

pharmaceutical-technology.com

retailwire.com

biopharmadive.com

Managed Healthcare Executive

drugtopics.com

420 Intel

CDR – Chain Drug Review

auntminnie.com

pharmtech.com

bariatricnews.net

daily-remedy.com

FDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease

FDA approves Novo Nordisk’s diabetes drug Ozempic for chronic kidney disease

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics